Sun Pharma Advanced Research Company Limited (SPARC)
ISIN: INE232I01014 Industry: Drug Manufacturers—Specialty & Generic Sector: Healthcare Website
219.9
3.45(1.59%)

Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, and dermatology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders; and HitGen Ltd. to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited

Pricing Updates

TODAY'S HIGH

224.6

TODAY'S LOW

215

52 WEEK HIGH

349

52 WEEK LOW

201

Major Holders

% of Shares Held by
All Insider

77.24%

% of Shares Held by
Institutions

1.89%

% of Float Held by
Institutions

8.28%

Number of Institutions
Holding Shares

16

Company Overview

MARKET CAP

5982.62 Cr.

ETERPRISE VALUE

5970.88 Cr.

NO. OF SHARES

27.18 Cr.

BOOK VALUE

1.182

DIV. YIELD

None%

DEBT

79.22 Cr.

GROSS PROFIT

115.55 Cr.

CASH

12.88 Cr.

REVENUE

137.24 Cr.

REVENUE/SHARE

5.216

OHLC Chart 1y 2y 5y 10y

Price Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Volumes Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Cashflows

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Investments-4.77 Cr.2.63 Cr.208.75 Cr.-93.56 Cr.
Change To Liabilities-19.36 Cr.-60.17 Cr.71.77 Cr.-19.40 Cr.
Total cashflows from Investing Activities-29.17 Cr.1.56 Cr.155.34 Cr.-102.18 Cr.
Net Borrowings-157.64 Cr.167.41 Cr.57.42 Cr.-64.92 Lakhs
Total Cash from Financing Activities229.32 Cr.159.28 Cr.55.46 Cr.274.24 Cr.
Other Liabilities3.46 Cr.13.84 Cr.36.07 Cr.11.82 Cr.
Total Assets409.26 Cr.409.26 Cr.409.26 Cr.366.66 Cr.
Net Income-203.40 Cr.-151.13 Cr.-312.40 Cr.-145.43 Cr.
Change in Cash-8.07 Cr.8.95 Cr.27 k14.66 Lakhs
Effect of Exchange Rate017 k17 k17 k
Total Cash from Operating Activities-208.22 Cr.-151.89 Cr.-210.80 Cr.-171.91 Cr.
Depreciation10.16 Cr.10.71 Cr.9.36 Cr.7.50 Cr.
Other Cashflows from Investing Activities18 Lakhs10.66 Lakhs24.20 Lakhs3.95 Cr.
Dividends Paid0000
Change to Inventory0000
Change to Account Receivables-10.15 Cr.-1.54 Cr.-5.83 Cr.7.40 Cr.
Other Cashflows from Financing Activities-22.30 Cr.-8.12 Cr.-1.96 Cr.-91.77 Cr.
Change to Net Income11.07 Cr.7.70 Cr.-9.89 Cr.-33.86 Cr.
Capital Expenditures-32.68 Cr.-5.99 Cr.-54.04 Cr.-12.95 Cr.

Financials

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Research Development108.43 Cr.188.22 Cr.168.92 Cr.147.89 Cr.
Effect of Accounting ChargesNoneNoneNoneNone
Income Before Tax-203.40 Cr.-151.13 Cr.-312.40 Cr.-145.43 Cr.
Minority InterestNoneNoneNoneNone
Net Income-196.91 Cr.-145.70 Cr.-314.95 Cr.-152.11 Cr.
Selling General Administrative164.21 Cr.141.45 Cr.135.50 Cr.137.14 Cr.
Gross Profit115.55 Cr.220.09 Cr.24.86 Cr.165.53 Cr.
Ebit-196.91 Cr.-145.70 Cr.-314.95 Cr.-152.11 Cr.
Operating Income-196.91 Cr.-145.70 Cr.-314.95 Cr.-152.11 Cr.
Other Operating Expenses29.66 Cr.25.34 Cr.26.04 Cr.25.16 Cr.
Interest Expense-13.33 Cr.-10.65 Cr.-2.67 Cr.-9.39 Lakhs
Extraordinary ItemsNoneNoneNoneNone
Non RecurringNoneNoneNoneNone
Other ItemsNoneNoneNoneNone
Income Tax Expense0000
Total Revenue137.25 Cr.252.95 Cr.76.81 Cr.182.86 Cr.
Total Operating Expenses334.16 Cr.398.65 Cr.391.76 Cr.334.98 Cr.
Cost of Revenue21.70 Cr.32.85 Cr.51.95 Cr.17.33 Cr.
Total Other Income Expense Net-6.49 Cr.-5.43 Cr.2.55 Cr.6.68 Cr.
Discontinued OperationsNoneNoneNoneNone
Net Income from Continuous Ops.-203.40 Cr.-151.13 Cr.-312.40 Cr.-145.43 Cr.
Net Income Applicable to Common Shares-203.40 Cr.-151.13 Cr.-312.40 Cr.-145.43 Cr.

Balance Sheet

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Intangible Assets23.12 Cr.68.50 Lakhs29.37 Cr.57.07 Lakhs
Capital Surplus0940.45 Cr.940.45 Cr.940.45 Cr.
Total Liabilities248.85 Cr.397.94 Cr.291.20 Cr.102.23 Cr.
Stock Holder Equity31.23 Cr.-168.25 Cr.-18.63 Cr.296.23 Cr.
Minority Interest0000
Other Liabilities17.18 Cr.6.94 Cr.9.21 Cr.7.08 Cr.
Total Assets280.08 Cr.229.68 Cr.272.56 Cr.398.47 Cr.
Common Stock27.19 Cr.26.20 Cr.26.20 Cr.26.20 Cr.
Retained Earnings0-1134.90 Cr.-985.29 Cr.-670.42 Cr.
Other Liabilities74.99 Cr.47.87 Cr.49.46 Cr.6.10 Cr.
Good Will0000
Treasury Stock4.04 Cr.000
Other Assets90.70 Cr.70.78 Cr.69.44 Cr.59.41 Cr.
Cash1.22 Cr.9.30 Cr.35.23 Lakhs34.96 Lakhs
Current Liabilities171.42 Cr.233.35 Cr.235.35 Cr.95.04 Cr.
Long Term Asset Charges0000
Short Long Term Debt75 Cr.38.04 Cr.54.52 Lakhs54.52 Lakhs
Other Stockholder Equity4.04 Cr.000
Property Plant Equipment95.12 Cr.95.10 Cr.106.55 Cr.81.11 Cr.
Total Cur. Assets71.14 Cr.63.11 Cr.67.18 Cr.257.38 Cr.
Long Term Investments0000
Net Tangible Assets8.11 Cr.-168.93 Cr.-48.01 Cr.295.66 Cr.
Short Term Investments11.66 Cr.000
Net Receivables30.92 Cr.17.64 Cr.16.81 Cr.10.72 Cr.
Long Term Debt0112.50 Cr.54.52 Lakhs1.09 Cr.
Inventory079.61 Lakhs2.48 Cr.4.93 Cr.
Accounts Payable72.18 Cr.99.06 Cr.158.84 Cr.82.92 Cr.

New Offers


Upstox offer
Upstox

Open a demat account through us and get the account opening charges waived off

open paperless account